Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Romanian Journal of Internal Medicine
Volume 60 (2022): Issue 3 (September 2022)
Open Access
Intravenous treatment adherence of patients with chronic inflammatory rheumatic diseases during the COVID-19 pandemic: experience of a single center
Hatice Ecem Konak
Hatice Ecem Konak
,
Berkan Armağan
Berkan Armağan
,
Serdar Can Güven
Serdar Can Güven
,
Ebru Atalar
Ebru Atalar
,
Özlem Karakaş
Özlem Karakaş
,
Serdar Esmer
Serdar Esmer
,
Mehmet Akif Eksin
Mehmet Akif Eksin
,
Bünyamin Polat
Bünyamin Polat
,
Hakan Apaydin
Hakan Apaydin
,
Kevser Gök
Kevser Gök
,
İsmail Doğan
İsmail Doğan
,
Abdulsamet Erden
Abdulsamet Erden
,
Yüksel Maraş
Yüksel Maraş
,
Orhan Küçükşahin
Orhan Küçükşahin
,
Ahmet Omma
Ahmet Omma
and
Şükran Erten
Şükran Erten
| Sep 22, 2022
Romanian Journal of Internal Medicine
Volume 60 (2022): Issue 3 (September 2022)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Sep 22, 2022
Page range:
173 - 181
Received:
Apr 28, 2022
DOI:
https://doi.org/10.2478/rjim-2022-0010
Keywords
coronavirus
,
infliximab
,
intravenous infusion
,
patient adherence
,
rheumatology
,
rituximab
© 2022 Hatice Ecem Konak et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.